Position in LLY
as of Jun 30, 2026
· filed Jul 16, 2026
Position Value
$22,597,262
+$14,218,158 QoQ
Shares Held
18,840
+106.8% QoQ
Ownership
0.002%
of shares outstanding
% of Portfolio
1.67%
of 13F equity value
Holder Rank
#840
of 4,605 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in LLY Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Sava Infond d.o.o. holds $59,832,598 across 10 Drug Manufacturers - General names. LLY ranks #1 (37.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
This page
|
18,840 | $22,597,262 | |
| 2 | AZN |
Astrazeneca PLC
|
70,580 | $13,383,378 | |
| 3 | MRK |
Merck & Co., Inc.
|
88,000 | $11,308,000 | |
| 4 | ABBV |
AbbVie Inc.
|
21,692 | $5,458,574 | |
| 5 | JNJ |
Johnson & Johnson
|
16,905 | $4,293,362 | |
| 6 | AMGN |
Amgen Inc
|
2,850 | $1,032,042 | |
| 7 | NVO |
Novo Nordisk A S
|
20,725 | $993,556 | |
| 8 | GILD |
Gilead Sciences, Inc.
|
2,740 | $346,171 |
All Filings in LLY
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $22,597,262 | 18,840 | Shares | Defined | 2026-07-16 | |
| 2026-03-31 | $8,379,104 | 9,110 | Shares | Defined | 2026-05-11 | |
| 2025-12-31 | $10,048,258 | 9,350 | Shares | Defined | 2026-01-29 | |
| 2025-09-30 | $7,217,980 | 9,460 | Shares | Sole | 2025-11-10 | |
| 2025-06-30 | $7,452,306 | 9,560 | Shares | Sole | 2025-07-22 | |
| 2025-03-31 | $7,970,031 | 9,650 | Shares | Sole | 2025-04-23 | |
| 2024-12-31 | $7,418,920 | 9,610 | Shares | Sole | 2025-02-12 | |
| No filing history on record for this holder in this stock. | ||||||